The present convention concerns the use of a pancreatic organ or tissue graft for the manufacture of a medicament identified for treating a pancreatic disorder associated with a pathological organ or tissue physiology or morphology, the pancreatic organ or tissue graft selected not substantially expressing or presenting at least one molecule capable of stimulating or enhancing an immune response in a subject and wherein the pancreatic organ or tissue graft is non-human.
